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Background
In the UK randomised clinical trials mainly register with
the ISRTN and ClinGov. However, the quality of reporting
is poor. No studies have identified moving beyond the
minimum data set for prospective registration to include
conduct, performance, cost and results of trials.
Objectives
To test the feasibility of specified questions under six
themes (origin of topic, trial conduct and performance,
statistical and economic analyses, and trial costs). To pilot
a database structured around those questions.
Methods
We assessed the NIHR HTA portfolio for all published
randomised clinical trials from 1999 to 2011.
The feasibility element explored the operationalisation
of 85 proposed questions. Each question was assessed for
data availability, time needed to extract and analyse data.
Questions deemed feasible were eligible for full data
extraction in the pilot study.
Results
109 HTA funded projects published in the HTA Journal
Series met inclusion criteria (a randomised clinical trial).
Of the 85 original questions, seven were deemed not fea-
sible. 78 questions were eligible for the pilot study. Each
question was judged on completeness, amendments,
skills and resource. Of the 78 questions, 33 were recom-
mended to ‘keep’, 28 for ‘amend’ and 17 to ‘drop’.
Conclusions
Our findings suggest that it is feasible to move beyond a
limited minimum dataset. Extending the database to
include all NIHR clinical trials could help to better
understand the conduct, performance, analyses and cost
of trials. To maximise the added value of their funding
of trials with high quality science, metadata on those
trials is essential.
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